Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

brain lesions

3 posts
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Genentech fenebrutinib cuts relapsing MS relapses 51%-59%

  • 2026-05-02
04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
RRoche
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
Read More

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

  • 2026-04-27
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
RRoche
Genentech persevERA breast cancer trial misses PFS goal
Read More

Roche fenebrutinib cuts RMS relapses 51%-59%

  • 2026-04-22
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…
Switzerland
www.europesays.com